157 related articles for article (PubMed ID: 30819683)
1. Immune checkpoint inhibitor-induced rheumatoid arthritis: insights into an increasingly common aetiology of polyarthritis.
Kwok TSH; Bell MJ
BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30819683
[TBL] [Abstract][Full Text] [Related]
2. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
[TBL] [Abstract][Full Text] [Related]
3. Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response.
Smith MH; Bass AR
Arthritis Care Res (Hoboken); 2019 Mar; 71(3):362-366. PubMed ID: 29125905
[TBL] [Abstract][Full Text] [Related]
4. Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.
Subedi A; Williams SG; Yao L; Maharjan S; Strauss J; Sharon E; Thomas A; Apolo AB; Gourh P; Hasni SA; Gulley JL; Kaplan MJ; Katz JD; Gupta S
JAMA Netw Open; 2020 Feb; 3(2):e200032. PubMed ID: 32101306
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
Kostine M; Truchetet ME; Schaeverbeke T
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
[TBL] [Abstract][Full Text] [Related]
7. Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.
Albayda J; Bingham CO; Shah AA; Kelly RJ; Cappelli L
Rheumatology (Oxford); 2018 Apr; 57(4):760-762. PubMed ID: 29342300
[No Abstract] [Full Text] [Related]
8. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.
Kosche C; Owen JL; Choi JN
Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735010
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report.
Abe K; Ishikawa Y; Fujiwara M; Yukawa H; Yanagihara T; Takei S; Arioka H; Kita Y
Medicine (Baltimore); 2022 Jan; 101(2):e28428. PubMed ID: 35029182
[TBL] [Abstract][Full Text] [Related]
10. [A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma].
Tomizawa M; Nakai Y; Maesaka F; Owari T; Hara R; Miyake M; Inoue T; Anai S; Tanaka N; Fujimoto K
Hinyokika Kiyo; 2018 Oct; 64(10):397-401. PubMed ID: 30543737
[TBL] [Abstract][Full Text] [Related]
11. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor.
Mathew Thomas V; Bindal P; Ann Alexander S; McDonald K
J Oncol Pharm Pract; 2020 Mar; 26(2):459-461. PubMed ID: 30909794
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
[TBL] [Abstract][Full Text] [Related]
14. Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.
Venetsanaki V; Boutis A; Chrisoulidou A; Papakotoulas P
Curr Oncol; 2019 Feb; 26(1):e111-e114. PubMed ID: 30853817
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy.
Murray-Brown W; Wilsdon TD; Weedon H; Proudman S; Sukumaran S; Klebe S; Walker JG; Smith MD; Wechalekar MD
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571993
[TBL] [Abstract][Full Text] [Related]
17. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy.
Johnson ED; Kerrigan K; Butler K; Patel SB
J Oncol Pharm Pract; 2020 Jan; 26(1):224-227. PubMed ID: 30880569
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab-induced aplastic anemia: A case report and literature review.
Comito RR; Badu LA; Forcello N
J Oncol Pharm Pract; 2019 Jan; 25(1):221-225. PubMed ID: 28825374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
